Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues revised labeling for GlaxoSmithKline’s Serevent, Advair, but continues to negotiate changes to Novartis/Schering’s Foradil.